$20.59
2.14% today
Nasdaq, Oct 03, 10:08 pm CET
ISIN
US81750R1023
Symbol
MCRB

Seres Therapeutics Inc Stock price

$21.04
+1.52 7.79% 1M
+7.48 55.16% 6M
+4.42 26.59% YTD
+2.99 16.59% 1Y
-102.76 83.00% 3Y
-532.76 96.20% 5Y
-501.96 95.98% 10Y
-1,006.96 97.95% 20Y
Nasdaq, Closing price Thu, Oct 02 2025
+0.54 2.63%
ISIN
US81750R1023
Symbol
MCRB
Industry

Key metrics

Basic
Market capitalization
$184.2m
Enterprise Value
$138.8m
Net debt
positive
Cash
$45.4m
Shares outstanding
8.8m
Valuation (TTM | estimate)
P/E
- | 68.4
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.6
Financial Health
Equity Ratio
9.9%
Return on Equity
1.0%
ROCE
-
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-81.6m
EBIT
- | $-102.4m
Net Income
- | $2.7m
Free Cash Flow
$-60.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 27.5%
EBIT
- | 13.2%
Net Income
- | 1,821.4%
Free Cash Flow
67.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-6.9
Short interest
17.4%
Employees
103
Rev per Employee
$0.0
Show more

Is Seres Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Seres Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Seres Therapeutics Inc forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Seres Therapeutics Inc forecast:

Buy
70%
Hold
30%

Financial data from Seres Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 56 56
33% 33%
-
- Research and Development Expense 66 66
52% 52%
-
-120 -120
25% 25%
-
- Depreciation and Amortization 5.47 5.47
12% 12%
-
EBIT (Operating Income) EBIT -126 -126
22% 22%
-
Net Profit 0.14 0.14
100% 100%
-

In millions USD.

Don't miss a Thing! We will send you all news about Seres Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Seres Therapeutics Inc Stock News

Neutral
GlobeNewsWire
10 days ago
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies
Neutral
Reuters
11 days ago
Enterprise software maker Oracle on Monday named insiders Clay Magouyrk and Mike Sicilia as co-CEOs, replacing Safra Catz, who was named vice chair of the board after 11 years at the helm.
Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00 p.m. ET on September 8, 2025.
More Seres Therapeutics Inc News

Company Profile

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Eric Shaff
Employees 103
Founded 2010
Website www.serestherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today